Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 5/20 | 0.55 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | MLNR | O43193 | 2/20 | 0.55 |
| ▸ | GMNN | O75496 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24709131 | 0.81 | CACNA1G (0.76) | CACNA1GCACNA1HSLC6A2OPRM1SMN1; SMN2 | |
| SCHEMBL30079786 | 0.81 | CACNA1G (0.76) | CACNA1GCACNA1HSLC6A2OPRM1SMN1; SMN2 | |
| SCHEMBL10281563 | 0.81 | OPRM1 (0.65) | CACNA1GCACNA1HSLC6A2OPRM1SMN1; SMN2 | |
| SCHEMBL1152634 | 0.79 | OPRM1 (0.60) | CACNA1GCACNA1HSLC6A2OPRM1SMN1; SMN2 | |
| SCHEMBL12205223 | 0.78 | CACNA1G (0.50) | CACNA1GCACNA1HOPRM1OPRK1CYP3A4 | |
| SCHEMBL8478720 | 0.78 | CACNA1G (0.52) | CACNA1GCACNA1HOPRM1NPSR1OPRK1 | |
| SCHEMBL8058238 | 0.78 | CACNA1G (0.48) | CACNA1GCACNA1HOPRM1SMN1; SMN2NPSR1 | |
| SCHEMBL11929305 | 0.77 | HTR2A (0.68) | CACNA1GCACNA1HSLC6A2OPRM1SMN1; SMN2 | |
| SCHEMBL14515353 | 0.76 | CACNA1G (0.46) | CACNA1GCACNA1HOPRM1OPRK1OPRL1 | |
| SCHEMBL8059497 | 0.75 | OPRL1 (0.48) | CACNA1GCACNA1HOPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-3989707-A | NEUROLEPTIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CACNA1G 3832/4885CACNA1H 4234/4885SLC6A2 3501/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | CACNA1G 3832/4885CACNA1H 4234/4885SLC6A2 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.